The FACS/FISH/Confocal Microscopy Core provides functional, phenotypic, cell cycle, genotypic and structural analysis to the investigators of this program project. The laboratory has developed cutting edge techniques in single cell analysis. For the quantitation of apoptotic cells, the TdT-b-dUTP assay (TUNEL) was modified for multiparameter analysis in combination with DMA and BUdR measurements (cell cycle, ploidy). Also, phenotypic analysis of stem and progenitor cells (Project 1), analysis of intracellular proteins related to apoptosis (p53, MDM2, bcl-2, bax, XIAP) (Project 1), and of cell surface antigens including fas and MDR1 is provided. Expression of new regulators of apoptosis proteins (Projects 1, 2) will be analyzed in normal and leukemic cells. Binding of Annexin V to phosphatidyl serine (PS) is utilized for testing changes in the membrane lipid structure associated with apoptosis. A newly developed assay identifies apoptotic cells (PS/Annexin V+) in the AML stem cell compartment (CD34+38""""""""123*). New assays to measure changes in the mitochondrial membrane potential and of cytochrome c in cells initiating apoptosis (CMXRos) and the detection of cleaved caspase 3 are conducted for Projects 1,2,3 and 4. Quantitation of cellular antigens allows us to determine the Antibody Binding Capacity (ABC). CD34 cells are MACS separated for subsequent analysis by FACS. Cell kinetic changes are determined by DNA/Ki67/ CD34/CD38 FCM and the number of actual cell divisions is determined by PKH26 labeling, with cells undergoing none or up to ten divisions being separated by FACS for subsequent molecular analysis (Project 1). Fluorescence in situ hybridization (FISH) determines the number of clonal leukemic interphase or metaphase cells (Projects 4, 5) before and after treatment with the CXCR4 inhibitor AMD3100. The combination of FISH and TUNEL or PS/Annexin V assays allows us to discriminate apoptosis in normal and leukemic cells (Projects 1 and 3) in mixed cell populations. Finally, progenitor and stem cell compartments (CD34+38~, CD34 38~123+ and CD34"""""""" lin"""""""" cells that eliminate Hoechst 33342, so-called """"""""SP"""""""" cells) are sorted for determination of mRNA and protein levels by RPPA. Projects 1 and 2, are analyzed for the presence of clonal leukemic and normal cells. Many of the clinical trial translational studies (BH3 mimetic GX015-070MS, XIAP antisense AEG35156, Raf inhibitor BAY 43-9006 and CXCR4 inhibitor AMD3100 in Projects 4 and 5 are being conducted in Core B1. In addition to multiparametric flow cytometry and cell sorting, the Core provides Laser Scanning Cytometry for quantitation of antigen/proteins in single cells. Importantly, laser confocal microscopy has become an indispensable tool for analysis of intracellular localizations of many proteins, e.g. p53 and AIF (Projects 1,2). The Core provides critical support for all Projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055164-19
Application #
8334647
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2014-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
19
Fiscal Year
2011
Total Cost
$148,622
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Zeng, Zhihong; Liu, Wenbin; Tsao, Twee et al. (2017) High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 102:1537-1548
Carter, Bing Z; Mak, Po Yee; Wang, Xiangmeng et al. (2017) Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16:1133-1144
Jacamo, Rodrigo; Davis, R Eric; Ling, Xiaoyang et al. (2017) Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget 8:83354-83369
Pan, Rongqing; Ruvolo, Vivian; Mu, Hong et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell 32:748-760.e6
Carter, Bing Z; Mak, Po Yee; Chen, Ye et al. (2016) Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NF?B/IL1? signaling network. Oncotarget 7:20054-67
Pemmaraju, Naveen; Kantarjian, Hagop; Ravandi, Farhad et al. (2016) Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk 16:213-222.e2
Ruvolo, Peter P; Ruvolo, Vivian R; Benton, Christopher B et al. (2016) Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochim Biophys Acta 1863:562-71
Takahashi, Koichi; Kantarjian, Hagop; Garcia-Manero, Guillermo et al. (2016) Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clin Lymphoma Myeloma Leuk 16:163-8.e1-2
Zeng, Zhihong; Wang, Rui-Yu; Qiu, Yi Hua et al. (2016) MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget 7:55083-55097

Showing the most recent 10 out of 417 publications